Candesartan for Migraine Prevention:
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Migraine
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: A multicentre, binational, triple blind, placebo controlled, parallel group study of two dosesMasking: Triple (Participant, Care Provider, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 64 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04574713
- Collaborators
- Norwegian University of Science and Technology
- Nordlandssykehuset HF
- Molde Hospital
- Haukeland University Hospital
- Sorlandet Hospital HF
- University Hospital, Akershus
- Ullevaal University Hospital
- Rikshospitalet University Hospital
- University Hospital of North Norway
- Tartu University Hospital
- Investigators
- Study Director: Christian Samsonsen, md phd St Olavs Hospital, Dept Neurology & Clinical Neurophysiology Study Director: Jorunn L Helbostad, prof Norwegian University of Science and Technology, Fac MH, Dept INB Principal Investigator: Erling Tronvik, md prof Norwegian University of Science and Technology, Fac MH, Dept INB
Get Well Soon